Results 11 to 20 of about 38,527 (248)

Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker. [PDF]

Pharmacol Res Perspect
ABSTRACT There is increasing evidence, from cellular, animal and human epidemiological studies, linking β‐blockers with reductions in cancer growth and metastasis. Propranolol is the most investigated β‐blocker for cancer; although as many different off‐patent β‐blockers exist, there is little commercial incentive to drive comparative clinical trials ...
Baker JG.
europepmc   +2 more sources

Linking FHIR-Based Medication Data to a Computable Algorithm for Heart Medication Optimization: A Critical Component of Any Medication Learning Health System. [PDF]

Learn Health Syst
ABSTRACT Introduction Despite strong evidence supporting guideline‐directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), a significant gap persists in the consistent application of these therapies. This shortfall has prompted organizations like the American College of Cardiology to recommend leveraging electronic ...
LeGrand J, Ali MS, Flynn A, Arzac J, Lester C, Dorsch MP.   +5 more
europepmc   +2 more sources

Mechanism of carvedilol induced action potential and calcium alternans

Channels, 2022
Carvedilol is a nonspecific β-blocker clinically used for the treatment of cardiovascular diseases but has also been shown to have profound effects on excitation-contraction coupling and Ca signaling at the cellular level. We investigate the mechanism by
Elizabeth Martinez-Hernandez, Giedrius Kanaporis, Lothar A. Blatter   +2 more
doaj   +1 more source

In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches

Scientific Reports, 2023
The pandemic of coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a significant impact on the economy and public health worldwide.
Chunye Zhang, Jiazheng Liu, Yuxiang Sui, Shuai Liu, Ming Yang   +4 more
doaj   +1 more source

Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF ...
Brian Schwartz, Colin Pierce, Christian Madelaire, Morten Schou, Søren Lund Kristensen, Gunnar H. Gislason, Lars Køber, Christian Torp‐Pedersen, Charlotte Andersson   +8 more
doaj   +1 more source

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin [PDF]

, 2018
Objective: Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection.
Abrar, Mohammed Burhan, Abuosa, Ahmed Mohamed, Ahmed, Adel H., Andejani, Abdulwahab, Cleland, John G.F., Elshiekh, Ayman Hassan, Kholeif, Mona A., Kinsara, Abdulhalim Jamal, Qureshi, Kahekashan   +8 more
core   +1 more source

Chitosan as Valuable Excipient for Oral and Topical Carvedilol Delivery Systems

Pharmaceuticals, 2021
Chitosan is a valued excipient due to its biocompatibility properties and increasing solubility of poorly water-soluble drugs. The research presented in this paper concerns the preparation of binary combinations of chitosan (deacetylated chitin) with ...
Szymon Sip, Magdalena Paczkowska-Walendowska, Natalia Rosiak, Andrzej Miklaszewski, Katarzyna Grabańska-Martyńska, Karolina Samarzewska, Judyta Cielecka-Piontek   +6 more
doaj   +1 more source

Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias

Journal of Cardiovascular Development and Disease, 2022
The study investigates the prognostic role of treatment with carvedilol as compared to metoprolol in patients with ventricular tachyarrhythmias. A large retrospective registry was used including consecutive patients on beta-blocker (BB) treatment with ...
Tobias Schupp, Michael Behnes, Mohammad Abumayyaleh, Kathrin Weidner, Jonas Rusnak, Kambis Mashayekhi, Thomas Bertsch, Ibrahim Akin   +7 more
doaj   +1 more source

The Potential Benefits of Using Garlic Oil and Its Active Constituent, Dially Disulphide, in Combination With Carvedilol in Ameliorating Isoprenaline-Induced Cardiac Damage in Rats

Frontiers in Pharmacology, 2021
Garlic oil and its primary component, diallyl disulphide (DADS), were tested in rats with isoprenaline (ISO) induced myocardial infarction for cardioprotective benefits when combined with carvedilol.
Syed Mohammed Basheeruddin Asdaq, Obulesu Challa, Abdulhakeem S. Alamri, Abdulhakeem S. Alamri, Walaa F. Alsanie, Walaa F. Alsanie, Majid Alhomrani, Majid Alhomrani, Mohammed Asad   +8 more
doaj   +1 more source

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources